Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in EuropeBoehringer Ingelheim ’s PRRS vaccine celebrates 25 years of presence in EuropeThe Company has been offering a holistic approach to veterinarians and producers to control PRRS through collaborative research, innovative diagnostics and services (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news
real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211 EMPRISE data complement the la...
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news
reduced-heart-failure-treatment-approval-europe
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe, with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults with ins...
Source: Boehringer Ingelheim Corporate News - June 21, 2021 Category: Research Source Type: news
founding-member-of-QUTAC
Quantum Computing: Boehringer Ingelheim is a Founding Member of QUTACTen leading German companies form this newly created Quantum Technology and Application ConsortiumTogether, the members want to explore industrial applications for quantum computingQuantum computing has also great potential for pharmaceutical research and development (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 9, 2021 Category: Research Source Type: news
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaksLifebit ’s deep learning, Natural Language Processing and Artificial Intelligence platform automatically detects and tracks global infectious disease outbreaks using real-world evidenceThe captured insights can accelerate detection of the latest outbreaks including transboundary diseases and emerging pathogens (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH FDA ’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH.Boehringer Ingelheim ’s focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news
BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim ’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy DesignationBI 425809, a novel glycine transporter-1 (Gly-T1) inhibitor to be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 24, 2021 Category: Research Source Type: news
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news
collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 10, 2021 Category: Research Source Type: news
Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolioBoehringer Ingelheim continues to stay at the forefront of innovation and provide producers with the right tools for disease preventionThe Company ’s Ubroseal® Blue brings confidence of best practice when it comes to sealant administration and removal (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news
expanded-collaboration-MD-Anderson
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC) The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and ObesityNew studies mark an important advancement of Boehringer Ingelheim ’s cardiometabolic focus areas obesity and NASH.The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvementThe Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 13, 2021 Category: Research Source Type: news
PREVEXXION ® RN: Marek’s disease vaccine available in EU UK
PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UKPREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balanceThe product ’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strainsIt is also fully compatible with VAXXITEK ® HVT+IBD and available in the same ampoule for added convenience (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2021 Category: Research Source Type: news
2020-Positive-business-momentum-despite-COVID-19-impact
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19 Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7% to 3.7 billion EUR in 2020 (18.9% of net sales) Outlook 2021: slight year-on-year increase in net sales on a comparable basis (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 23, 2021 Category: Research Source Type: news
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric DisordersThrough the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia. The new collaboration further expands Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and solidifies the company’s commitment to provide better treatments for patients living with se...
Source: Boehringer Ingelheim Corporate News - March 16, 2021 Category: Research Source Type: news
